Abciximab

1
Abciximab
Brands

DEA Class; Rx

Common Brand Names; ReoPro

  • Antiplatelet Agents, Cardiovascular; 
  • Glycoprotein IIb/IIIa Inhibitors

Platelet glycoprotein IIb/IIIa receptor antagonist
Adjunctive therapy for preventing cardiac ischemic complications in percutaneous coronary intervention (PCI) or in patients with unresponsive unstable angina
Fab fragment of the chimeric monoclonal antibody 7E3

Indicated for the Prevention of cardiac ischemic complications in patients undergoing PCI

Indicated for prevention of cardiac complications in patients with unstable angina with PCI planned within 24 hr

Adjunctive therapy during thrombolysis (off-label)

Hypersensitivity

Active internal bleeding

Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance

History of CVA (within 2 years) or CVA with a significant residual neurological deficit

Bleeding diathesis

Administration of oral anticoagulants within seven days unless prothrombin time is ≤1.2 times control

Thrombocytopenia (< 100,000 cells/μL)

Recent (within six weeks) major surgery or trauma

Intracranial neoplasm, arteriovenous malformation, or aneurysm

Severe uncontrolled hypertension

Presumed or documented history of vasculitis

  • Bleeding, minor (70-82%)
  • Bleeding, major (17-21%)
  • Hypotension (14-21%)
  • Back pain (17.6%)
  • Nausea (13.6%)
  • Chest pain (11.4%)
  • Vomiting (7-11%)
  • Headache (6%)
  • Thrombocytopenia (2-6%)
  • Bradycardia (5%)
  • Injection site pain (3.6%)
  • Extremity pain (3.5%)
  • Abdominal pain (3%)
  • UTI (2%)
  • Dizziness (1.8%)
  • Peripheral edema (1.6%)
  • Anemia (1.2%)
  • Diarrhea (1%)
  • Hypoesthesia (1%)

Intended for use with aspirin and heparin, and has only been studied in that setting

Allergic reactions, some of which were anaphylaxis (sometimes fatal), reported rarely in patients receiving therapy; patients with allergic reactions should receive appropriate treatment; treatment of anaphylaxis should include immediate discontinuation of therapy and initiation of resuscitative measures

In the event of serious uncontrolled bleeding or need for emergency surgery, therapy should be discontinued; if platelet function does not return to normal, it may be restored, at least in part, with platelet transfusions

Pregnancy Category: C

Lactation: not known if excreted in breast milk; use caution

Adults

2,000 mg/day PO.

Geriatric

2,000 mg/day PO.

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Abciximab

injectable solution

  • 2mg/mL
DrugsAce
Logo